The evolution of aldosterone antagonists

@article{Garthwaite2004TheEO,
  title={The evolution of aldosterone antagonists},
  author={Susan M. Garthwaite and Ellen G. Mcmahon},
  journal={Molecular and Cellular Endocrinology},
  year={2004},
  volume={217},
  pages={27-31}
}
Since the isolation and purification of aldosterone from adrenal extracts 50 years ago (Experientia 9 (1953) 33), scientists have learned a great deal about how and where aldosterone acts, the factors that control its release, what is its role in the pathophysiology of cardiovascular disease, how to make and study aldosterone antagonists, and for what medical purposes these agents are useful. In this paper, we will discuss the evolution of aldosterone antagonists from the relatively… Expand
Interfering with mineralocorticoid receptor activation: the past, present, and future
TLDR
Advances have been made that could potentially increase the clinical use of agents that inhibit the actions of aldosterone, and these will be discussed here along with some examples of the beneficial effects of these new therapeutic agents. Expand
The importance of renin-angiotensin blockade in patients with cardio-renal disease.
TLDR
The continued discovery of yet more components of this system promises to further the authors' understanding of its influence on disease processes and herald the development of more highly selective drugs, ensuring that the renin-angiotensin-aldosterone system will continue to be a key area of interest for many years to come. Expand
The risks and benefits of aldosterone antagonists
  • D. Sica
  • Medicine
  • Current heart failure reports
  • 2005
TLDR
For most patients the risk of developing hyperkalemia should not dissuade the prudent clinician from use of spironolactone and eplerenone, but as enthusiasm grows for use of mineralocorticoid-blocking agents, the risks inherent to use of such drugs become more pertinent. Expand
Pharmacological treatment of aldosterone excess.
TLDR
Clinical research will provide the answers as to which drugs and strategies to treat high-aldosterone states are the most effective, calling for specific anti-ald testosterone drugs. Expand
Mineralocorticoid receptor antagonists: their use and differentiation in Japan
  • A. Sato
  • Medicine
  • Hypertension Research
  • 2013
TLDR
In Japan, it is necessary to carefully differentiate spironolactone from eplerenone in regard to their intended uses, and this differentiation is divided into two types due to the differences in their features and Differences in their contraindications in Japan. Expand
Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
TLDR
It is demonstrated that the molecular pharmacology of current MR antagonists is on the one hand far from well understood and, on the other hand, still offers room for improvements. Expand
Discovery of BAY 94‐8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
TLDR
An extended SAR exploration starting from cyano‐1,4‐dihydropyridines that were identified by high‐throughput screening led to the identification of a dihydronaphthyridine, BAY 94‐8862, which is a potent, selective, and orally available nonsteroidal MR antagonist currently under investigation in a clinical phase II trial. Expand
Mineralocorticoids in the heart and vasculature: new insights for old hormones.
TLDR
Interference with the interaction between MR and its coregulators seems to be a promising strategy toward the development of selective MR modulators. Expand
Comparison of agents that affect aldosterone action.
The first aldosterone blocker, spironolactone, initially was used as a diuretic but was accompanied by a significant amount of side effects that necessitated the withdrawal of the drug in a relevantExpand
Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension.
TLDR
A narrative review summarizes the knowledge on the use of classic MRAs in hypertension and covers the evidence currently available on new aldosterone blockers. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.
  • E. Mcmahon
  • Medicine
  • Current opinion in pharmacology
  • 2001
TLDR
New preclinical data generated over the past few years strongly support the hypothesis that aldosterone has important deleterious effects on the cardiovascular system independent of the classical action of this hormone on renal epithelial cells. Expand
Eplerenone: a selective aldosterone receptor antagonist (SARA).
TLDR
In rodent models, eplerenone provides marked protection against vascular injury in the kidney and heart and is well tolerated in acute and chronic safety pharmacology studies, which will extend the understanding of selective aldosterone receptor antagonism in the treatment of chronic cardiovascular disease. Expand
Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors.
TLDR
The structure-affinity relationships of various 19-nor spirolactones show greater, equivalent or lesser affinity vis-a-vis their parent compounds should define one of the determinants of pharmacologic activity. Expand
Antiandrogenic effect of spirolactones: mechanism of action.
TLDR
It seems likely that spirolactones, besides their action on testosterone biosynthesis, exert their antiandrogenic activity via a peripheral androgen antagonism. Expand
THE METABOLISM AND BIOPHARMACEUTICS OF SPIRONOLACTONE IN MAN
TLDR
It was demonstrated that after a single oral dose of spironolactone, 7 alpha-thiomethylspirolactone is the main metabolite and that unchanged spironlactone reaches maximum serum concentrations which are in the same order of magnitude as canrenone. Expand
The metabolic effects of progesterone in man.
TLDR
It has been demonstrated that progesterone induces growth in the sebaceous glands of rats, and in a man with Addison's disease who was maintained with added salt, 30 mg. Expand
SC 25152: a potent mineralocorticoid antagonist with decreased antiandrogenic activity relative to spironolactone.
TLDR
It is demonstrated that the antiandrogenic and antimineralocorticoid activities of spironolactone analogs can be dissociated and the utility of measurements of drug-receptor interaction to identify a compound with desired pharmacological properties is illustrated. Expand
Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro.
TLDR
It appears that the 9 alpha, 11 alpha-position of the steroid structure is a site of the molecule which can be modified to improve the specificity of aldosterone-antagonists not only in vitro, but also in vivo. Expand
SC 25152: A potent mineralocorticoid antagonist with reduced affinity for the 5 alpha-dihydrotestosterone receptor of human and rat prostate.
TLDR
One spironolactone analog was found to have considerably reduced affinity for the prostate 5 alpha-dihydrotestosterone receptor while maintaining similar affinity forThe mineralocorticoid receptors of human and rat kidney, which would predict this analog to have reduced antiandrogenicity at equivalent therapeutic doses. Expand
Effects of the Selective Aldosterone Blocker Eplerenone Versus the Calcium Antagonist Amlodipine in Systolic Hypertension
TLDR
Eplerenone was as effective as amlodipine in lowering systolic BP and pulse pressure as well as pulse wave velocity in older patients with widened pulse pressure hypertension and reduced microalbuminuria to a greater extent in this older patient group. Expand
...
1
2
3
4
...